ND0612: a skin pump for round-the-clock levodopa moves through Phase 3

Mitsubishi Tanabe Pharma America will present new results on ND0612 at the International Congress of Parkinson’s Disease and Movement Disorders (Honolulu, 5–9 October). ND0612 is an investigational 24-hour, continuous under-the-skin infusion of liquid levodopa/carbidopa. In plain English, it is a small wearable pump that drips the standard Parkinson’s medicine into the body steadily, rather than in stop-start tablets. The data come from BouNDless, a pivotal Phase 3 study comparing ND0612 with current standard care in people who have motor fluctuations (good “ON” periods and troublesome “OFF” time between doses). The study looked at the big outcomes that matter day to day: more ON time, less OFF time, how the drug levels behave in the blood (pharmacokinetics), and the impact across different disease stages. It also examined dyskinesia (involuntary movements) and functional outcomes, including a new analysis on falls. Four posters will cover: how the continuous skin delivery changes levodopa levels over 24 hours whether benefits are consistent in milder versus more advanced Parkinson’s what happens to dyskinesia with ND0612 compared with tablets whether people fell less often on ND0612 in BouNDless Why this matters Levodopa works brilliantly, but tablets can produce peaks and dips. For many, that means hours lost to OFF time, early wearing-off, and dose-to-dose unpredictability. A reliable, low-effort, 24-hour delivery could smooth control without the invasiveness of intestinal gel surgery, while keeping to a familiar medicine. What it does not mean (yet) ND0612 is not approved. We do not have the full peer-reviewed results from BouNDless here, only the company’s congress summaries. Key questions remain: size of benefit on ON/OFF time, effect on dyskinesia, pump comfort and skin reactions, device reliability, sleep and night-time control, and how it compares with existing advanced options (intestinal gel, apomorphine infusion, DBS). Bottom line Continuous levodopa under the skin is a logical next step for people whose tablets no longer last. These Phase 3 readouts are an important milestone. If ND0612 proves it adds meaningful ON time without troublesome side effects and is practical to live with, it could become another tool to smooth the day for those with motor fluctuations. As always, decisions will come down to individual goals, tolerability, and access.